Sutro Biopharma (STRO) Depreciation & Amortization (CF) (2017 - 2025)

Sutro Biopharma has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $1.6 million in Q4 2025.

• Quarterly Depreciation & Amortization (CF) fell 12.22% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (up 1.72% YoY) and the FY2025 annual result came in at $7.3 million, up 1.72% from the prior year.
• Depreciation & Amortization (CF) fell to $1.6 million in Q4 2025 per STRO's latest filing, from $1.9 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.9 million in Q1 2025 and troughed at $1.1 million in Q3 2021.
• A 5-year average of $1.6 million and a median of $1.7 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) rose 28.62% in 2022, then retreated 12.22% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.3 million in 2021, then grew by 21.01% to $1.5 million in 2022, then advanced by 11.51% to $1.7 million in 2023, then rose by 7.87% to $1.8 million in 2024, then declined by 12.22% to $1.6 million in 2025.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.6 million, $1.9 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.